Pfizer Validates Coley Pharmaceutical's ProMune#8482; with Deal Worth US$515 M Plus
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 59 (Table of Contents)
Published: 1 May-2005
DOI: 10.3833/pdr.v2005.i59.678 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
In what would be the largest value licensing deal of 2005 so far, Pfizer has agreed to develop, manufacture and commercialise Coley Pharmaceutical Group's Phase II oligonucleotide therapeutic, ProMune#8482; (CpG 7909), which has broad applicability as an anticancer therapy...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS